Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

[Efficacy and safety of sildenafil in patients with systemic scleroderma].

Alekperov RT, Ananyeva LP, Korzeneva EG, Cheremukhina EO.

Ter Arkh. 2013;85(5):60-7. Russian.

PMID:
23819341
2.

Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.

Kumar U, Sankalp G, Sreenivas V, Kaur S, Misra D.

Rheumatol Int. 2013 Apr;33(4):1047-52. doi: 10.1007/s00296-012-2466-5. Epub 2012 Jul 26. Erratum in: Rheumatol Int. 2013 Apr;33(4):1053. Gokhle, Sankalp S [corrected to Sankalp, Gokhale].

PMID:
22833239
3.

Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.

Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, Vázquez-Abad MD, Denton CP.

Arthritis Rheum. 2011 Mar;63(3):775-82. doi: 10.1002/art.30195.

4.

Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.

Garg N, Sharma MK, Sinha N.

Int J Cardiol. 2007 Sep 3;120(3):306-13. Epub 2006 Dec 15.

PMID:
17174417
5.

Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.

Abou-Raya A, Abou-Raya S, Helmii M.

J Rheumatol. 2008 Sep;35(9):1801-8. Epub 2008 Aug 15.

PMID:
18709692
6.

Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.

Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, Burmester G, Riemekasten G.

Ann Rheum Dis. 2010 Aug;69(8):1475-8. doi: 10.1136/ard.2009.116475. Epub 2009 Nov 8.

7.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.

Eur Respir J. 2007 Mar;29(3):469-75. Epub 2006 Nov 1.

8.

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Fries R, Shariat K, von Wilmowsky H, Böhm M.

Circulation. 2005 Nov 8;112(19):2980-5.

9.

[Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].

Rosenkranz S, Caglayan E, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E.

Dtsch Med Wochenschr. 2004 Aug 13;129(33):1736-40. German.

PMID:
15295684
11.

[Sildenafil therapy for pulmonary hypertension: a prospective study].

Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Zeng WJ, Zhu F, He JG.

Zhonghua Jie He He Hu Xi Za Zhi. 2011 Jun;34(6):419-23. Chinese.

PMID:
21781512
12.

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.

Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.

Arthritis Rheum. 1998 Apr;41(4):670-7.

PMID:
9550476
13.

Acute and long-term efficacy and safety of sildenafil for the treatment of chronic thromboembolic pulmonary hypertension in a heart transplant recipient.

Zacà V, Padeletti M, Pagliaro A, Furiozzi F, Mondillo S, Favilli R.

Pharmacology. 2011;87(1-2):24-7. doi: 10.1159/000322531. Epub 2010 Dec 20.

PMID:
21178386
14.

Efficacy and safety of high dose generic sildenafil in Thai patients with pulmonary arterial hypertension.

Durongpisitkul K, Pornrattanarungsi S, Panjasamanvong P, Chungsomprasong P.

J Med Assoc Thai. 2011 Apr;94(4):421-6.

PMID:
21591526
15.

[Sex, erectile dysfunction, and the heart: a growing problem].

Görge G, Flüchter S, Kirstein M, Kunz T.

Herz. 2003 Jun;28(4):284-90. Review. German.

PMID:
12825143
16.

Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?

Amin A, Mahmoudi E, Navid H, Chitsazan M.

Congest Heart Fail. 2013 Mar-Apr;19(2):99-103. doi: 10.1111/chf.12008. Epub 2012 Dec 12.

17.

Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?

Madden BP, Sheth A, Wilde M, Ong YE.

Vascul Pharmacol. 2007 Aug-Sep;47(2-3):184-8. Epub 2007 Jun 18.

PMID:
17627899
18.

Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction.

Afif-Abdo J, Teloken C, Damião R, Koff W, Wroclawski E, Yamasaki R, Torres LO, Sabaneeff J, Faria G, Pompeo AC, Cortado P, Glina S.

BJU Int. 2008 Sep;102(7):829-34. doi: 10.1111/j.1464-410X.2008.07767.x. Epub 2008 Jun 4.

19.

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2002 Sep;46(9):2410-20.

20.

One year efficacy and safety of oral sildenafil treatment in severe pulmonary hypertension.

Samarzija M, Zuljević E, Jakopović M, Sever B, Knezević A, Dumija Z, Vidjak V, Samija M.

Coll Antropol. 2009 Sep;33(3):799-803.

PMID:
19860106

Supplemental Content

Support Center